In Situ Antigen‐Capturing Nanochaperone Toward Personalized Nanovaccine for Cancer Immunotherapy

• DOI: 10.1002/smll.202203100
• Publication Date: 2022-07-18T02:17:35Z
• Authors: Xue Li; Yongxin Zhang; Xiaohui Wu; Jiajing Chen; Menglin Yang; Feihe Ma; Linqi Shi
• Keywords: Cancer Immunotherapy; Immune checkpoint

Abstract Personalized cancer vaccination using nanomaterials holds great potential for immunotherapy. Here, a nanochaperone (PBA‐nChap) is tailored in situ capture of tumor‐associated antigens (TAAs) to improve The PBA‐nChap capable i) efficiently capturing TAAs situ; ii) protecting from degradation; iii) transporting antigen‐presenting cells and promoting cross‐presentation. Intratumor injection combination with pretreatment photodynamic therapy (PDT) significantly enhances immune response exhibits excellent antitumor efficacy. Moreover, nanovaccine prepared by simply co‐culturing tumor cell fragments surgery resected primary vitro synergized checkpoint blockade (ICB) can effectively inhibit recurrence metastasis after an operation. This work provides promising platform personalized vaccination.